Marker Therapeutics, Inc.
Business
Marker Therapeutics is a clinical-stage immuno-oncology company developing MAR-T cell therapies, which are non-genetically modified T cell products designed to recognize and kill cancer cells expressing multiple tumor-associated antigens. The company is advancing two product candidates—MT-601 (autologous MAR-T for lymphoma and pancreatic cancer) and MT-401-OTS (off-the-shelf MAR-T for acute myeloid leukemia and myelodysplastic syndrome)—through Phase 1 clinical trials in the United States. Marker has licensed its core technology from Baylor College of Medicine and partners with contract manufacturing organizations and academic institutions to support manufacturing and clinical development.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 4 | 7 | 3 | 4 | 1 | |
| Research and development | 12 | 13 | 10 | 12 | 28 | |
| General and administrative | 4 | 4 | 7 | 11 | 13 | |
| Loss on early termination of vendor agreement | 453,135 | — | — | — | — | |
| Total operating expenses | 16 | 18 | 18 | 23 | 41 | |
| Loss from operations | −13 | −11 | −15 | −20 | −39 | |
| Interest income | 594,206 | 437,010 | 539,158 | 248,063 | 5,700 | |
| Other income | 117,444 | — | — | — | — | |
| Loss from operations before income taxes | −12 | −11 | −14 | −20 | — | |
| Income tax (benefit) expense | −15,156 | 49,953 | 4,000 | — | — | |
| Net loss | −12 | −11 | −8 | −30 | −42 | |
| Net loss per share, basic (in dollars per share) | −0.79 | −1.19 | −0.94 | −3.58 | −5.47 | |
| Net loss per share, diluted (in dollars per share) | −0.79 | −1.19 | −0.94 | −3.58 | −5.47 | |
| Basic (in shares) | 15 | 9 | 9 | 8 | 8 | |
| Diluted (in shares) | 15 | 9 | 9 | 8 | 8 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 16 | 19 | 15 | 12 | 42 | |
| Restricted cash | 1 | 0 | — | 0 | 1 | |
| Prepaid expenses and deposits | 658,750 | 483,717 | — | — | — | |
| Other receivables | 1 | 2 | 1 | 2 | 237 | |
| Total current assets | 19 | 22 | 17 | 17 | 46 | |
| Total assets | 19 | 22 | 17 | 34 | 68 | |
| Accounts payable and accrued liabilities | 1 | 2 | 2 | 3 | 11 | |
| Related party payable | — | 2 | 1 | — | — | |
| Deferred revenue | 974,799 | — | — | 0 | 1 | |
| Total current liabilities | 2 | 3 | 3 | 8 | 13 | |
| Total liabilities | 2 | 3 | 3 | 15 | 24 | |
| Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common stock, $0.001 par value, 30 million shares authorized, 16.7 million and 10.7 million shares issued and outstanding as of December 31, 2025 and 2024, respectively (see Note 7) | 16,672 | 10,708 | 8,891 | 8,406 | 8,308 | |
| Additional paid-in capital | 476 | 466 | 450 | 448 | 442 | |
| Accumulated deficit | −459 | −447 | −436 | −428 | −398 | |
| Total stockholders' equity | 17 | 19 | 14 | 20 | 44 | |
| Total liabilities and stockholders' equity | 19 | 22 | 17 | 34 | 68 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −12 | −11 | −8 | −30 | −42 | |
| Stock-based compensation | 537,540 | 245,864 | 858,269 | 3 | 6 | |
| Prepaid expenses and deposits | −175,033 | 504,409 | — | — | — | |
| Other receivables | 977,303 | −1 | — | — | — | |
| Related party payable | −2 | 380,845 | 1 | 3 | — | |
| Accounts payable and accrued expenses | −454,570 | 8,761 | −718,393 | −1 | 4 | |
| Deferred revenue | 974,799 | — | — | −1 | 1 | |
| Net cash used in operating activities | −12 | −11 | −16 | −27 | −27 | |
| Proceeds from issuance of common stock, net | 10 | 15 | 1 | 202,130 | 53 | |
| Proceeds from exercise of warrants and stock options | 605 | 62,159 | — | — | — | |
| Net cash provided by financing activities | 10 | 15 | 1 | 202,130 | 53 | |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | −2 | 4 | 3 | −32 | 22 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Marker Therapeutics, Inc.'s CIK number?
Marker Therapeutics, Inc.'s SEC CIK number is 0001094038 (1094038). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Marker Therapeutics, Inc.'s SEC filings?
All of Marker Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Marker Therapeutics, Inc. last report earnings?
Marker Therapeutics, Inc. (MRKR) most recently filed an earnings 8-K with the SEC on Mar 19, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-031309). This is Marker Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Marker Therapeutics, Inc.'s most recent earnings 8-K?
Marker Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 19, 2026 under accession 0001104659-26-031309. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Marker Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →